11.66
전일 마감가:
$13.07
열려 있는:
$12.86
하루 거래량:
971.76K
Relative Volume:
0.33
시가총액:
$18.47M
수익:
$74,000
순이익/손실:
$-13.43M
주가수익비율:
-1.2404
EPS:
-9.4
순현금흐름:
$-10.54M
1주 성능:
+252.27%
1개월 성능:
+3,320%
6개월 성능:
+102.43%
1년 성능:
-56.36%
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
명칭
Cyclacel Pharmaceuticals Inc
전화
908-517-7330
주소
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
CYCC을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CYCC
Cyclacel Pharmaceuticals Inc
|
11.66 | 5.24M | 74,000 | -13.43M | -10.54M | -9.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-07-18 | 재개 | Oppenheimer | Outperform |
2020-04-27 | 재개 | ROTH Capital | Buy |
2018-09-07 | 개시 | Ladenburg Thalmann | Buy |
2015-10-16 | 개시 | H.C. Wainwright | Buy |
2010-02-04 | 개시 | Roth Capital | Buy |
2009-10-28 | 개시 | Merriman | Buy |
2008-08-12 | 개시 | Piper Jaffray | Buy |
2008-03-12 | 재확인 | Cantor Fitzgerald | Buy |
2008-03-12 | 재확인 | Collins Stewart | Buy |
2008-03-12 | 재확인 | Needham & Co | Buy |
2007-11-27 | 재확인 | Cantor Fitzgerald | Buy |
2007-08-10 | 재확인 | Cantor Fitzgerald | Buy |
2007-06-04 | 재확인 | Needham & Co | Buy |
2007-04-23 | 개시 | Lazard Capital | Buy |
2007-04-10 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Cyclacel Pharmaceuticals Inc 주식(CYCC)의 최신 뉴스
Is Cyclacel Pharmaceuticals Inc. a good long term investmentDynamic profit opportunities - Autocar Professional
What analysts say about Cyclacel Pharmaceuticals Inc. stockExceptional market positioning - Autocar Professional
CYCC’s Financial Health: Exploring Cyclacel Pharmaceuticals Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Cyclacel Plunges 11.09% on Revenue Guidance Cut - AInvest
Wall Street Zen Downgrades Cyclacel Pharmaceuticals (NASDAQ:CYCC) to Sell - Defense World
Cyclacel Pharmaceuticals Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com
What drives Cyclacel Pharmaceuticals Inc. stock priceExceptional trading performance - jammulinksnews.com
CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD To Go Ex-Dividend On July 21st, 2025 With 0.15 USD Dividend Per Share - 富途牛牛
Big Moves And Bigger Questions For Biotech And Tech Stocks - Finimize
Cyclacel stock falls after paring 270% gain amid volatility concerns By Investing.com - Investing.com Canada
Cyclacel stock dips after trimming 270% surge amid volatility concerns - MSN
Cyclacel Shares Plunge 36% Amid Volatility, What's Driving the Sell-Off? - AInvest
Cyclacel stock falls after paring 270% gain amid volatility concerns - Investing.com Australia
Cyclacel Pharmaceuticals Addresses Recent Stock Price Volatility Amid Ongoing Business Developments - Quiver Quantitative
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY - Yahoo Finance
Cyclacel Pharmaceuticals Stock Plunges 37.23% - AInvest
Cyclacel Pharmaceuticals Stock Surges Amid Positive Research Findings - AInvest
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyHigh Potential Stock Ideas - beatles.ru
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
Cyclacel's Volatile Surge: Can This Biotech Stock Defy Gravity? - AInvest
Cyclacel Pharmaceuticals Stock Soars: Investing or Waiting? - timothysykes.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Fitters: US$1m cash added to Cyclacel deal to address stock volatility since signing - The Malaysian Reserve
Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS - MSN
Cyclacel stock soars after amendment to exchange agreement with FITTERS By Investing.com - Investing.com Nigeria
Cyclacel stock soars after amendment to exchange agreement with FITTERS - Investing.com Australia
Cyclacel sweetens Fitters acquisition deal with US$1m cash addition - The Malaysian Reserve
Cyclacel Pharmaceuticals Amends Exchange Agreement with FITTERS - TipRanks
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - The Manila Times
Breakthrough: New Drug Shows Effectiveness Against Untreatable Youth Liver Cancer, Research Reveals - Stock Titan
Cyclacel Pharmaceuticals adjusts shareholder rights, amends stock - MSN
Cyclacel Pharmaceuticals to Acquire Fitters Sdn. Bhd. Through Share Exchange Agreement - Global Legal Chronicle
Cyclacel Pharmaceuticals Announces 1-for-15 Reverse Stock Split Effective July 7, 2025 - Nasdaq
Cyclacel Pharmaceuticals Announces Stock Split - Morningstar
Cyclacel Announces Major Share Restructuring: 23.7M Shares Consolidating to 1.58M - Stock Titan
Cyclacel Pharmaceuticals shareholders re-elect directors and approve equity plan changes - Investing.com India
Cyclacel Pharmaceuticals Approves Equity Plan Amendment - TipRanks
Cyclacel Stock Tumbles Over 76% Since Regaining Nasdaq Compliance: What’s Ailing the Nanocap Biopharma Firm? - Investing.com India
Cyclacel Raises $3M Through Preferred Stock Deal: New Warrants Unveiled at $0.51-$0.68 Exercise Price - Stock Titan
Why Did Cyclacel Pharmaceuticals Inc. (CYCC) Soar 13.92%? - AInvest
Cyclacel Pharmaceuticals Inc (CYCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):